Search for 'an:"303" and au:Castellano, Daniel and itype:ART'

Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

By Castellano, Daniel. JCI insight, 2016 . 1(10):e86051. , Formato Vancouver: García Donas J, Beuselinck B, Inglada Pérez L, Graña O, Schöffski P, Wozniak A et al. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight. 2016 Jul 7;1(10):e86051.

Place Hold on Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

By Castellano, Daniel. Lancet (London, England), 2016 . 387(10031):1909-20. , Formato Vancouver: Rosenberg JE, Hoffman Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20.

Place Hold on Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.

By Villacampa Aubá, Felipe | Duarte Ojeda, José Manuel | Martínez, Victor | Gómez Rodríguez, María José | Martín, María Luisa | Fernández, Manoli | Castellano, Daniel | Rodríguez Peralto, José Luis | Rosa Kehrman, Federico de la . Molecular carcinogenesis, 2015 . 54(7):566-76. , Formato Vancouver: Dueñas M, Martínez Fernández M, García Escudero R, Villacampa F, Marqués M, Saiz Ladera C et al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog. 2015 Jul;54(7):566-76.

Place Hold on PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . 26(9):1987-93. , Formato Vancouver: Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep; 26(9):1987-93.

Place Hold on Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

By Castellano, Daniel. Cancer, 2020 . 126(18):4156-4167. , Formato Vancouver: Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020 Sep 15;126(18):4156-4167.

Place Hold on Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

By Castellano, Daniel. The New England journal of medicine, 2015 . 373(19):1803-13. , Formato Vancouver: Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.

Place Hold on Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

By Castellano, Daniel. British journal of cancer, 2015 . 113(1):12-9. , Formato Vancouver: Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015 Jun 30;113(1):12-9.

Place Hold on Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

By Castellano, Daniel. BMC cancer, 2015 . 15:495. , Formato Vancouver: Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015 Jul 4;15:495.

Place Hold on Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

By Castellano, Daniel. European urology, 2015 . 68(4):621-9. , Formato Vancouver: Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015 Oct;68(4):621-9.

Place Hold on CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.

By Castellano, Daniel. European journal of clinical pharmacology, 2015 . 71(12):1477-84. , Formato Vancouver: Diekstra MH, Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H et al. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2015 Dec;71(12):1477-84.

Place Hold on Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.

Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.

By Martínez Fernández, Mónica | Dueñas, Marta | Segovia, Cristina | Rubio, Carolina | Fernández, María | Villacampa Aubá, Felipe | Duarte Ojeda, José Manuel | López Calderón, Fernando F | Gómez Rodríguez, María José | Castellano, Daniel | Rosa Kehrman, Federico de la | Rodríguez Peralto, José Luis | Paramio, Jesús M.. Clinical epigenetics, 2015 . 7:109. , Formato Vancouver: Martínez Fernández M, Feber A, Dueñas M, Segovia C, Rubio C, Fernandez M et al. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clin Epigenetics. 2015 Oct 8;7:109.

Place Hold on Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

By Castellano, Daniel. European urology, 2015 . 67(5):904-12. , Fórmato Vancouver: Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S et al. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol. 2015 May;67(5):904-12.

Place Hold on Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.

Place Hold on A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

By Castellano, Daniel. BMC cancer, 2014 . 14:779. , Formato Vancouver: Castellano D, Puente J, de Velasco G, Chirivella I, López Criado P, Mohedano N et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014 Oct 24;14:779.

Place Hold on Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

By Castellano, Daniel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014 . 32(2):76-82. , Formato Vancouver: Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014 Jan 10;32(2):76-82.

Place Hold on Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology, 2014 . 25(11):2173-8. , Formato Vancouver: Aparicio J, Maroto P, García Del Muro X, Sánchez Muñoz A, Gumà J, Margelí M et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014 Nov;25(11):2173-8.

Place Hold on Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

By Castellano, Daniel | Ghanem Cañete, Ismael. Cancer chemotherapy and pharmacology, 2014 . 73(4):857-67. , Formato Vancouver: Castellano DE, Bellmunt J, Maroto JP, Font Pous A, Morales Barrera R, Ghanem I et al. Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67.

Place Hold on Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.

Place Hold on In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

By Castellano, Daniel. Cancer medicine, 2014 . 3(6):1517-26. , Formato Vancouver: Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014 Dec;3(6):1517-26.

Place Hold on Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma.

By Castellano, Daniel. PloS one, 2014 . 9(1):e86263. , Formato Vancouver: Prior C, Pérez-Gracia JL, García-Donas J, Rodríguez-Antona C, Guruceaga E, Esteban E et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One. 2014 Jan 24;9(1):e86263.

Place Hold on Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma.

Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.

By Castellano, Daniel. Expert opinion on drug safety, 2014 . 13(9):1165-73. , Formato Vancouver: Castellano D, Antón Aparicio LM, Esteban E, Sánchez-Hernández A, Germà JR, Batista N et al; cabazitaxel EAP study. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Expert Opin Drug Saf. 2014 Sep;13(9):1165-73.

Place Hold on Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

By Castellano, Daniel | Sepúlveda Sánchez, Juan Manuel. Expert opinion on drug safety, 2014 . 13(4):497-510 , Formato Vancouver: Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E et al. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf. 2014 Apr;13(4):497-510. doi: 10.1517/14740338.2014.888413. .

Place Hold on Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

By Castellano, Daniel. The Lancet. Oncology, 2014 . 15(11):1263-8. , Formato Vancouver: Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN et al. Abiraterone Global EAP Investigators. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014 Oct;15(11):1263-8.

Place Hold on Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.

By Castellano, Daniel. BMC cancer 2013 . 13:427. , Formato Vancouver: Martín-Richard M, Massutí B, Pineda E, Alonso V, Marmol M, Castellano D. TTD (Tumores del Tracto Digestivo) Study Group. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 2013 Sep 20;13:427.

Place Hold on Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.

Prognostic Factors and Long-Term Outcome of Pancreatic Neuroendocrine Neoplasms: Ki-67 Index Shows a Greater Impact on Survival than Disease Stage. The Large Experience of the Spanish National Tumor Registry (RGETNE).

By Castellano, Daniel. Neuroendocrinology, 2013 . 98(2):156-68. , Formato Vancouver: Martín-Pérez E, Capdevila J, Castellano D, Jiménez-Fonseca P, Salazar R, Beguiristain-Gómez A et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology. 2013;98(2):156-68.

Place Hold on Prognostic Factors and Long-Term Outcome of Pancreatic Neuroendocrine Neoplasms: Ki-67 Index Shows a Greater Impact on Survival than Disease Stage. The Large Experience of the Spanish National Tumor Registry (RGETNE).

Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB).

By Castellano, Daniel. Oncology, 2013 . 85(4):208-15. , Formato Vancouver: Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E et al. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013;85(4):208-15.

Place Hold on Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB).

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

By Castellano, Daniel. Annals of Oncology, 2013 . 24(9):2409-14. , Formato Vancouver: Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013 Sep;24(9):2409-14.

Place Hold on Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.

By Castellano, Daniel. Cancer and Metastasis Reviews, 2013 . 32(3-4):465-77. , Formato Vancouver: De Dosso S, Grande E, Barriuso J, Castellano D, Tabernero J, Capdevila J. The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation. Cancer Metastasis Rev. 2013 Dec;32(3-4):465-77.

Place Hold on The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.

HIVEC con mitomicina C. Actualizacion y resultados en pacientes de alto riesgo.

By Guerrero Ramos, Félix | Castellano, Daniel | García Rojo, Esther | Duarte Ojeda, José Manuel | Villacampa Aubá, Felipe | Rosa Kehrman, Federico de la . Archivos Españoles de Urología, 2018 . 71(4):417-425. , Formato Vancouver: Guerrero-Ramos F, Castellano-Gauna D, García-Rojo E, Duarte-Ojeda JM, de la Rosa-Kehrmann F, Villacampa-Aubá F. HIVEC con mitomicina C. Actualizacion y resultados en pacientes de alto riesgo. Arch Esp Urol. 2018 May;71(4):417-425.

Place Hold on HIVEC con mitomicina C. Actualizacion y resultados en pacientes de alto riesgo.

Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.

By Castellano, Daniel. Expert opinion on drug safety, 2013 . 12(4):455-63. , Formato Vancouver: Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernández Pastor LJ et al. Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opin Drug Saf. 2013 Jul;12(4):455-63.

Place Hold on Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.

By Castellano, Daniel. Oncologist, 2013 . 18(1):46-53. , Formato Vancouver: Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T et al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18(1):46-53.

Place Hold on Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).

By Castellano, Daniel. European Journal of Cancer, 2013 . 49(18):3780-7. , Formato Vancouver: Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, García-Carbonero R et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer. 2013 Dec;49(18):3780-7.

Place Hold on Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma.

By Castellano, Daniel | López Martín, José Antonio. Clinical Cancer Research, 2013 . 19(5):1257-68. , Formato Vancouver: Angevin E, López-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013 Mar;19(5):1257-68.

Place Hold on Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma.

Tratamiento hormonal en la recidiva bioquímica tras prostatectomía radical.

By Rodríguez Antolín, Alfredo | Castellano, Daniel | Domínguez Esteban, Mario | Díaz González, Rafael | Duarte Ojeda, José Manuel | Romero Otero, Javier | Cabeza Rodríguez, Mª Ángeles | Díez Sicilia, Laura. Archivos Españoles de Urología, 2012 . 2012:65(1):111-21. , Formato Vancouver: Rodríguez Antolín A, Castellano D, Domínguez Esteban M, Díaz González R, Duarte Ojeda JM, et al. Tratamiento hormonal en la recidiva bioquínica tras la prostactemía radical. Arch Esp Urol. 2012;65(1):111-21.

Place Hold on Tratamiento hormonal en la recidiva bioquímica tras prostatectomía radical.

The role of pharmacogenomics in metastatic renal cell carcinoma.

By Castellano, Daniel | Sepúlveda Sánchez, Juan Manuel. Cancer and Metastasis Reviews, 2012 . 146(3):117-20. , Formato Vancouver: Castellano D, Virizuela JA, Cruz J, Sepulveda JM, Sáez MI, Paz-Ares L. The role of pharmacogenomics in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S29-32.

Place Hold on The role of pharmacogenomics in metastatic renal cell carcinoma.

Recomendaciones sobre el manejo de controversias en cáncer de próstata avanzado resistente a la castración.

By Castellano, Daniel. Actas Urológicas Españolas, 2012 . 36(10):569-77. , Formato Vancouver: Cózar JM, Solsona E, Morote J, Miñana B, Maroto JP, González Del Alba A,et al. Recomendaciones sobre el manejo de controversias en cáncer de próstata avanzado resistente a la castración. Actas Urol Esp. 2012 Nov-Dec;36(10):569-77.

Place Hold on Recomendaciones sobre el manejo de controversias en cáncer de próstata avanzado resistente a la castración.

Recommendations for the optimal management of early and advanced urothelial carcinoma.

By Castellano, Daniel. Cancer Treatment Reviews, 2012 . 38(5):431-41. , Formato Vancouver: Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, et al. Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat Rev. 2012 Aug;38(5):431-41.

Place Hold on Recommendations for the optimal management of early and advanced urothelial carcinoma.

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?.

By Castellano, Daniel. Cancer and Metastasis Reviews, 2012 . 31(1-2):47-53. , Formato Vancouver: Grande E, Capdevila J, Barriuso J, Antón-Aparicio L, Castellano D. Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?. Cancer Metastasis Rev. 2012 Jun;31(1-2):47-53.

Place Hold on Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

By Castellano, Daniel. European Journal of Cancer, 2012 . 48(3):324-32. , Formato Vancouver: Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012 Feb;48(3):324-32.

Place Hold on An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

Cáncer de próstata resistente a castración: ¿hacia dónde vamos?.

By Castellano, Daniel. Actas Urológicas Españolas, 2012 . 36(6):367-74. , Formato Vancouver: Alcaraz A, Medina R, Maroto P, Climent MÁ, Castellano D, Carles J. Cáncer de próstata resistente a castración: ¿hacia dónde vamos?. Actas Urol Esp. 2012 Jun;36(6):367-74.

Place Hold on Cáncer de próstata resistente a castración: ¿hacia dónde vamos?.

Biological markers of cisplatin resistance in advanced testicular germ cell tumours

By Ballestín Carcavilla, Claudio | Castellano, Daniel | Cortés-Funes Castro, Hernán. Clinical and Translational Oncology, 2012 . 14(6):452-457. , Formato Vancouver: García-Velasco A, Durán I, García E, Tarón M, Ballestín C, Castellanos D, et al. Biological markers of cisplatin resistance in advanced testicular germ cell tumours. Clin Transl Oncol. 2012;14(6):452-7.

Place Hold on Biological markers of cisplatin resistance in advanced testicular germ cell tumours

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

By Castellano, Daniel. Lancet, 2011 . 378(9807):1931-1939. , Formato Vancouver: Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-9.

Place Hold on Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

By Castellano, Daniel. Cancer and Metastasis Reviews, 2011 . 30(Suppl 1):19-26. , Formato Vancouver: Raymond E, Hobday T, Castellano D, Reidy Lagunes D, García Carbonero R, Carrato A. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2011 Mar;30(Suppl 1):19-26.

Place Hold on Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Current knowledge on diagnosis and staging of neuroendocrine tumors

By Castellano, Daniel. Cancer and Metastasis Reviews, 2011 . 30(Suppl 1):3-7. , Formato Vancouver: Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 (Suppl 1):3-7.

Place Hold on Current knowledge on diagnosis and staging of neuroendocrine tumors

Tumores testiculares: cirugía de masas retroperitoneales residuales tras tratamiento quimioterápico; ¿es posible predecir su histología?

By Castellano, Daniel | Díaz González, Rafael | Medina Polo, José | Villacampa Aubá, Felipe | Rosa Kehrman, Federico de la . Archivos Españoles de Urología, 2011 . 64(7):611-619. , Formato Vancouver: Medina-Polo J, Martínez-Silva V, Domínguez-Esteban M, de la Rosa-Kehrmann F, Villacampa-Aubá F, Castellano-Gauna D, et al. Tumores testiculares: cirugía de masas retroperitoneales residuales tras tratamiento quimioterápico; ¿es posible predecir su histología?. Arch Esp Urol. 2011;64(7):611-9.

Place Hold on Tumores testiculares: cirugía de masas retroperitoneales residuales tras tratamiento quimioterápico; ¿es posible predecir su histología?

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

By Castellano, Daniel. Lancet Oncology, 2011 . 12(12):1143-1150. , Formato Vancouver: García Donas J, Esteban E, Leandro García LJ, Castellano DE, Del Alba AG, Climent MA, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011;12(12):1143-50.

Place Hold on Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives

By Castellano, Daniel | Cortés-Funes Castro, Hernán | García Escobar, Ignacio | Sepúlveda Sánchez, Juan Manuel. Critical Reviews in Oncology/Hematology, 2011 . 80(1):100-113. , Formato Vancouver: García-Escobar I, Sepúlveda J, Castellano D, Cortés-Funes H. Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives. Crit Rev Oncol Hematol. 2011;80(1):100-13.

Place Hold on Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives

Gastroenteropancreatic neuroendocrine tumors. Where are we now?

By Castellano, Daniel. Cancer Metastasis Reviews, 2011 . 30(Suppl 1):1. , Formato Vancouver: Castellano D. Gastroenteropancreatic neuroendocrine tumors. Where are we now? Cancer Metastasis Rev. 2011;30 Suppl 1:1.

Place Hold on Gastroenteropancreatic neuroendocrine tumors. Where are we now?

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

By Castellano, Daniel. Annals of Oncology, 2011 . 22(12):2646-2653. , Formato Vancouver: Bellmunt J, González Larriba JL, Prior C, Maroto P, Carles J, Castellano D, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646-53.

Place Hold on Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

By Castellano, Daniel | Sepúlveda Sánchez, Juan Manuel. Expert Opinion on Pharmacotherapy, 2011 . 12(16):2433-2439. , Formato Vancouver: Castellano D, González-Larriba JL, Antón-Aparicio LM, Cassinello J, Grande E, Esteban E, et al. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Expert Opin Pharmacother. 2011 Nov;12(16):2433-9.

Place Hold on Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients